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Abstract
Autosomal recessive polycystic kidney disease (ARPKD; MIM 263200) is a severe, typically 
early onset form of cystic disease that primarily involves the kidneys and biliary tract. Phenotypic 
expression and age at presentation can be quite variable1. The incidence of ARPKD is 1 in 20,000 
live births2, and its pleotropic manifestations are potentially life-threatening. Optimal care requires 
proper surveillance to limit morbidity and mortality, knowledgeable approaches to diagnosis and 
treatment, and informed strategies to optimize quality of life. Clinical management therefore is 
ideally directed by multidisciplinary care teams consisting of perinatologists, neonatologists, 
nephrologists, hepatologists, geneticists, and behavioral specialists to coordinate patient care from 
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the perinatal period to adulthood. In May 2013, an international team of 25 multidisciplinary 
specialists from the US, Canada, Germany, and the United Kingdom convened in Washington, 
DC, to review the literature published from 1990 to 2013 and to develop recommendations for 
diagnosis, surveillance, and clinical management. Identification of the gene PKHD1, and the 
significant advances in perinatal care, imaging, medical management, and behavioral therapies 
over the past decade, provide the foundational elements to define diagnostic criteria and establish 
clinical management guidelines as the first steps towards standardizing the clinical care for 
ARPKD patients. The key issues discussed included recommendations regarding perinatal 
interventions, diagnostic criteria, genetic testing, management of renal and biliary-associated 
morbidities, and behavioral assessment. The meeting was funded by the National Institutes of 
Health and an educational grant from the Polycystic Kidney Disease Foundation. Here we 
summarize the discussions and provide an updated set of diagnostic, surveillance, and 
management recommendations for optimizing the pediatric care of patients with ARPKD. 
Specialist care of ARPKD-related complications including dialysis, transplantation, and 
management of severe portal hypertension will be addressed in a subsequent report. Given the 
paucity of information regarding targeted therapies in ARPKD, this topic was not addressed in this 
conference.”
Keywords




As an autosomal recessive trait, ARPKD has a recurrence risk of 25%, regardless of sex.
PKHD1 gene and fibrocystin/polyductin (FPC) protein—PKHD1 is a large gene 
extending over a ~500-kb genomic segment on chromosome 6p123. The longest open 
reading frame comprises 66 exons that encode fibrocystin/polyductin complex (FPC). There 
is evidence for extensive alternative splicing; whether all the predicted alternative PKHD1 
transcripts are translated into proteins and what their biological functions may be it remains 
unknown. Overall, a critical amount of full-length protein seems to be required for sufficient 
biological function.
DNA-based diagnostic testing—The large size of PKHD1 poses significant challenges 
to current DNA sequencing methods. Other diagnostic challenges relate to the high 
frequency of missense mutations and private mutations in ‘non-isolate’ populations3. “In 
cases with strong clinical and/or histopathological evidence for ARPKD, mutation detection 
rates of about 80–85% have been demonstrated for the patients across the entire clinical 
spectrum1, 4. Several other cilia-related disease genes may mimic ("phenocopy") ARPKD. 
For instance, 2% of all ADPKD patients express an early onset, severe phenotype that is 
clinically indistinguishable from ARPKD5. Finally, the phenotype of ARPKD can also be 
mimicked by mutations in the HNF1B gene, which encodes the transcription factor, 
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hepatocyte nuclear factor-1beta (HNF1B), as well as by other gene defects that cause the 
hepatorenal fibrocystic diseases (HRFD; Table).
Expert opinion
• Given the high number of phenocopy disorders, mutational analysis of PKHD1 
using current single-gene testing methodologies should not be considered as a first-
line diagnostic approach for infants and children presenting with an ARPKD-like 
phenotype.
• Pathogenicity predictions for missense variants represent another diagnostic 
challenge; caution is required when only novel or rare missense changes are 
detected.
• More robust next generation sequencing methods that allow simultaneous 
investigation of multiple cystic kidney disease genes will increasingly become 
available.
Prenatal genetic diagnosis
Prenatal US detection of ARPKD is often not early enough for pregnancy termination.
Expert opinion
• At present, early and reliable prenatal diagnosis is only feasible by molecular 
genetic analysis using single-gene testing methodologies.
• Indirect, haplotype-based linkage analysis was performed for ARPKD before 
complete gene sequencing was widely available. Given the possibility of 
misdiagnosis, linkage analysis is no longer a diagnostic method of choice.
Genotype-phenotype correlations
Genotype–phenotype correlation for PKHD1 is hampered by a wide range of mutations, 
with children typically inheriting a different ARPKD mutation from each parent (compound 
heterozygotes)6. Practically all patients carrying two truncating mutations display a severe 
phenotype with peri- or neonatal demise, although exceptions have been reported7. In 
comparison, patients surviving the neonatal period usually bear at least one missense 
mutation; although the converse does not seem to apply and some missense changes can be 
as devastating as truncating mutations.
Expert opinion
• Caution must be exercised when predicting the clinical course from the genotype.
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• Standard second trimester ultrasound (US) imaging is usually sufficient to suggest 
the diagnosis of ARPKD, especially if findings include bilateral changes of large 
hyperechogenic kidneys with poor cortico-medullary differentiation.
• Macrocysts (>10 mm) in the fetal ARPKD kidney are unusual and suggest 
multicystic dysplasia; whereas bilateral cysts of 5–7 mm are reported in 29% of 
ARPKD cases8.
• A systematic evaluation should be undertaken for extra-renal anomalies, as other 
fetal conditions have been associated with renal hyperechogenicity. Of particular 
note, mutations in HNF1B have been shown in some studies to be the most 
common cause of fetal hyperechogenic kidneys9. Other associations include: 
Turner syndrome; Trisomies 8, 13, or 18; congenital cytomegalovirus infection; 
acyl-CoA dehydrogenase defects (glutaric aciduria type II); and the hepatorenal 
fibrocystic disorders (Table).
• In the context of severe oligohydramnios, fetal magnetic resonance imaging may 
better delineate the renal anatomy10.
• Amniocentesis should be considered for fetal karyotype and polymerase chain 
reaction for cytomegalovirus (CMV). Following transplacental passage, CMV 
typically infects the fetal kidney, which can result in sonographic evidence of 
increased renal echogenicity and oliogohydramnios in CMV-infected fetuses11.
• A complete three-generation family pedigree should be documented, particularly 
adult onset renal diseases and neonatal death related to pulmonary insufficiency or 
renal failure.
• Ultrasonography of the parents is recommended to screen for pre-symptomatic, 
dominant cystic kidney diseases, such as ADPKD or HNF1B-related disease.
Fetal monitoring
Once a presumptive diagnosis of ARPKD is made, US should be performed every 2 – 3 
weeks for serial assessment of the renal size and amniotic fluid volume. The gestational age 
(GA) at onset of oligohydramnios is variable in ARPKD. Onset of oligohydramnios in the 
second trimester may be associated with pulmonary hypoplasia and in one series, renal size 
>4 SD in association with oligohydramnios was associated with 100% perinatal mortality12. 
A study of 46 fetuses with severe genitourinary anomalies13 demonstrated that after 26 
weeks GA, a total lung volume value of <0.90 by magnetic resonance imaging has a 
sensitivity of 77.8% and specificity of 95% for predicting non-survival. A 3D US study 
showed that total fetal lung volume <5 %ile corrected for GA yielded a positive predictive 
value of 80% and a negative predictive value of 94% for lethal pulmonary hypoplasia.
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• Prenatal imaging does not provide precise prediction for the development of lethal 
neonatal pulmonary hypoplasia.
Perinatal management
After delivery, neonatal pulmonary status will usually dictate early management. When 
there has been a presumptive diagnosis of ARPKD, a mortality of 30–40% due to pulmonary 
hypoplasia has been reported14. Some infants with milder forms of pulmonary hypoplasia 
may respond well to high frequency ventilation. Persistent pulmonary hypertension (HTN) 
may be a prominent, but potentially reversible, component of the lung disease in the first 
days after birth that may respond to inhaled nitric oxide. In some cases, even extracorporeal 
membrane oxygenation may be appropriate if respiratory failure and/or pulmonary 
hypertension is not thought to be due to lethal lung hypoplasia. The potential need for 
dialysis in severely affected ARPKD neonates raises complex issues. Although survival of 
infants who initiate dialysis has improved significantly, mortality and morbidity remain 
concerning15.
Expert opinion
• Patients with a presumptive diagnosis of ARPKD should be referred for delivery at 
a facility with a level IV NICU16.
• Multidisciplinary prenatal consultation with input from maternal-fetal medicine, 
neonatology, and pediatric nephrology addressing delivery plans, neonatal 
respiratory illness, and short- and longer-term renal function should be arranged.
• A delivery plan should include the possibility of cesarean delivery for fetal 
abdominal dystocia due to renal enlargement.
• Given the lack of definitive fetal predictors of postnatal survival, decisions 
regarding aggressiveness of intervention both in labor and at delivery must take 
into account family preferences and all clinical information available at the time.
• The decision to offer (or withhold) dialysis should be made jointly by the treating 
physicians and the infant's parents. Peritoneal dialysis is the preferred modality17.
RENAL WORK GROUP
General Considerations
Diagnostics—ARPKD is suggested by characteristic hepatorenal involvement and a 
pedigree consistent with autosomal-recessive inheritance1.
Expert opinion
• Finding large echogenic kidneys with poor cortico-medullary differentiation 
bilaterally, and coexisting liver disease on standard diagnostic US imaging is 
usually sufficient for the diagnosis of ARPKD.
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• High resolution US may improve diagnostic sensitivity, particularly in mild 
disease6. Unlike in ADPKD, kidney size/volume do not correlate with renal 
function in ARPKD6.
• There may be phenotypic overlay with ADPKD and other HRFD (Table).
• In some patients, serial observation may be required to make the correct diagnosis.
• Genetic testing may facilitate the diagnosis in patients with suspected ARPKD.
Screening of siblings
Expert opinion
• ARPKD expression can be highly variable within sibships1, 18.
• Abdominal imaging of siblings into adulthood may be appropriate19. Genetic 
testing may be helpful in defining the affectation status of even apparently 
asymptomatic siblings if two pathogenic PKHD1 mutations have been identified in 
the index case.
Hypertension (HTN)—The prevalence of systemic HTN in children with ARPKD is 33–
75%1, 6, 18, 20. Marked HTN is often observed in the first months of life, and neonates with 
systemic HTN are statistically more likely to require mechanical ventilation (p<0.0001)1. 
The pathogenic mechanism remains poorly understood. Limited studies in humans and 
animal models suggest that activation of the intra-renal renin-angiotensin-aldosterone 
system, without concurrent elevation in systemic angiotensin I and II levels, may play a 
role21, 22. In addition, impaired urinary dilution with associated fluid retention and 
dysregulation of the collecting duct epithelial sodium channel may be contributing factors to 
ARPKD-related systemic HTN23, 24.
Expert opinion
• “The mainstays of current therapy are angiotensin converting enzyme inhibitors 
(ACEI) or angiotensin receptor blockers (ARB). Combination ACEI/ARB therapy 
is not recommended due to increased risk of side effects, without clear added 
benefit. Therapy should be directed towards optimizing blood pressure control, 
while minimizing further reduction in GFR in the context of chronic kidney disease 
(CKD)20.
• The recent multicenter ESCAPE trial in children with Chronic Kidney Disease 
stages 2–4 indicated that aggressive blood pressure control (target 24-hour mean 
arterial blood pressure below the 50th percentile for age, height and sex) may slow 
progression to end-stage renal disease25; the specific target for ARPKD has not 
been established.
Intracranial aneurysms—In contrast to ADPKD, intracranial aneurysms are rarely 
described with ARPKD26.
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• There is no evidence-based association between ARPKD and intracranial 
aneurysms.
• Routine screening of asymptomatic patients is not warranted.
Hyponatremia—Hyponatremia is common in ARPKD, with a reported incidence of 6–
26%1, 27. The mechanism likely involves impaired urinary dilution (rather than sodium 
wasting) leading to water overload, at a time when caloric and fluid intake is coupled and 
nutrition has a low osmotic load.
Expert opinion
• Standard treatment principles apply: in euvolemia or hypervolemia, fluid intake 
should be minimized without compromising nutrition, e.g. by concentrating feeds.
• Supplementation with sodium is likely to worsen HTN and should be avoided, 
unless there is evidence of hypovolemia.
• It is not known whether the hyponatremia is due to excessive vasopressin or tubulo-
interstitial dysfunction. Thus, vasopressin receptor blockers (Vaptans) are currently 
not recommended.
Postnatal Management/Recommendations—Even in newborns with massively 
enlarged kidneys, some renal function may be preserved and may transiently improve during 
the first months of life28. Given the often difficult issues with respiratory and nutritional 
support, unilateral or bilateral nephrectomy has been suggested to improve respiratory status 
or feeding. However, the risk of accelerating renal function loss and the consequent need for 
renal replacement therapy early in life must be carefully weighed. Dialysis 
recommendations for infants are addressed above.
Expert opinion
• The rationale for unilateral nephrectomy is based on few small nutrition 
studies29–31.
• There is no evidence that nephrectomy results in respiratory improvement.
• There is no evidence to support nephrectomy for severe HTN in early ARPKD.
LIVER WORK GROUP
General Considerations
Diagnostics—The primary liver disease in ARPKD is often referred to as congenital 
hepatic fibrosis (CHF) or ductal plate malformation and is manifest primarily by portal HTN 
and/or bile duct disease32. Portal HTN can cause splenomegaly with hypersplenism, and 
varices at risk for hemorrhage. Biliary disease may be very subtle, may not be appreciated 
by liver biochemistries or imaging studies, but can result in cholangitis. CHF is not typically 
associated with significant hepatobiliary inflammation or hepatic dysfunction; serum amino 
transferases and laboratory findings reflective of synthetic liver function (e.g. coagulation 
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profile) are normal or near normal. Therefore, a high index of suspicion is required to 
recognize advancing liver disease in children with ARPKD.
Expert opinion
• In the context of known ARPKD, CHF is presumed when portal HTN is present 
(see below) and biochemical evidence of liver disease is minimal (i.e. serum amino 
transferases <2 × upper limit of normal (ULN)), liver biopsy is not indicated and 
extensive investigation for other causes of liver disease is not necessary. However, 
portal vein thrombosis should be excluded by US.
• Portal HTN is defined by splenomegaly (i.e. spleen palpable >2 cm below the left 
costal margin or >1 cm larger than the ULN for age33) and thrombocytopenia with 
a value <150 mm3, or known varices, ascites, or hepatopulmonary syndrome.
• Cholangiopathy is defined by noninvasive radiologic demonstration of intra- or 
extra-hepatic biliary abnormalities. Of note, CHF-cholangiopathy with cholangitis 
may exist despite normal radiologic findings.
Anticipatory Guidance—Although uncommon, clinical manifestations of CHF (e.g. 
variceal hemorrhage and/or cholangitis) can be life-threatening34, requiring a heightened 
awareness and anticipatory guidance for possible complications. Even though still relatively 
low, the risk of mortality increases if treatment is delayed. Cholangitis, in particular, may be 
difficult to diagnose definitively; the classical triad of fever, jaundice, and right upper 
quadrant pain is rarely observed in children, and other more common causes of fever in 
childhood are often invoked. Although there is an increased risk of hepatobiliary cancer (e.g. 
cholangiocarcinoma and hepatocellular carcinoma) in individuals with CHF, this dreadful 
complication has not been described in individuals younger than 40 years of age34.
Expert opinion
• Hematemesis, hematochezia and/or melena require immediate medical attention 
(e.g. in an emergency facility with capacity for red blood cell transfusion).
• A high index of suspicion for cholangitis is required of those caring for ARPKD 
children.
• Hepatobiliary cancer is not a feature of ARPKD in childhood.
Screening—Screening for liver disease, especially complications of CHF, are warranted in 
children who have ARPKD. Features of portal HTN are the most frequent early 
manifestation of CHF and their identification permits anticipation of further complications. 
Liver biochemistries are not typically informative. Splenomegaly on physical examination is 
useful, but may be difficult to appreciate in a child with significant nephromegaly. Absence 
of splenomegaly does not exclude portal hypertension, however, so one should monitor for 
associated neutropenia or thrombocytopenia. There is no clear correlation between the 
severity of biliary abnormalities and the risk of cholangitis.
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• Care should be taken to identify splenomegaly on physical examination, with 
further evaluation by US (e.g. Doppler of the portal and splenic veins; 
measurement of maximal dimension of the spleen; and surveillance for intra- or 
extra-hepatic biliary dilatation).
• Annual complete blood and platelet count should be performed, with attention to 
the absolute counts, as well as the trends in these measurements.
• At 5 years of age, abdominal US should be performed, with attention to both intra- 
and extra-hepatic bile ducts and the maximal linear dimension of the spleen. If the 
initial studies are negative, follow up is recommended at least every 2 to 3 years.
• Suspicion for portal hypertension or biliary abnormalities should prompt a referral 
to a pediatric gastroenterologist/hepatologist. Once portal hypertension is verified, 
screening for associated complications follows standard guidelines35.
Prophylaxis—The utility of antibiotic prophylaxis for complications of CHF is not clearly 
established. Ursodeoxycholic acid (UDCA), with its choleretic effect, is theoretically useful 
in chronic cholestasis, but this does not apply to in most cases of CHF. Furthermore, 
randomized, placebo-controlled studies in adults with sclerosing cholangitis have identified 
a previously unknown potential toxicity of UDCA36; the relevance to CHF is unknown.
Expert opinion
• Routine antibiotic prophylaxis for cholangitis is not indicated.
• Antibiotic prophylaxis for 6 to 12 weeks after a cholangitis episode, immediately 
following transplantation, or in the context of enhanced immunosuppression may 
be considered.
• Approaches to prevention and treatment of varices are similar, if not identical, to 
approaches used in children with portal HTN from other causes and are typically 
decided upon by the subspecialist.
• The use of UCDA as a choleretic cannot be recommended.
Cholangitis and Hypersplenism—Complications of biliary disease and portal 
hypertension in ARPKD raise important considerations for the pediatrician. A diagnosis of 
cholangitis often necessitates a prolonged course of intravenous antibiotics and potentially 
worsens the prognosis of the CHF. Recurrent cholangitis is sometimes an indication for liver 
transplantation. Cytopenia in the context of portal HTN may unnecessarily raise concerns, as 
these blood count abnormalities are not typically associated with the same morbidities as 
cytopenias observed with bone marrow failure or related disorders. Similarly, symptoms like 
abdominal pain and anorexia are sometimes attributed to pronounced splenomegaly, 
although a causal relationship is difficult to prove. Perhaps the most vexing issue relates to 
splenomegaly and concerns about splenic injury when a portion of the spleen is unprotected 
by the rib cage.
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Expert opinion on cholangitis
◦ Cholangitis is a clinical diagnosis that can be difficult to definitively establish.
◦ Cholangitis should be considered in any ARPKD child with unexplained fever.
◦ An especially high index of suspicion is warranted in the first months after renal 
transplantation or when immunosuppression is high.
◦ Liver biopsy rarely yields a diagnosis of cholangitis and may represent a 
significant risk in the setting of biliary dilatation.
Expert opinion on cholangitis
◦ Hypersplenism-associated leukopenia does not typically increase infection risk.
◦ Splenectomy is rarely indicated as an isolated procedure.
◦ Limiting contact activities in individuals with a palpable spleen is highly 
controversial and not guided by evidence, but more by common sense.
NEUROCOGNITIVE/BEHAVIORAL WORK GROUP
In children and adolescents with ARPKD clinical features such as HTN and CKD 
predispose them to neurocognitive and social-behavioral challenges37, 38. In addition hepatic 
encephalopathy is well-described in individuals with renal dysfunction following 
portosystemic shunting (PSS) to relieve severe portal hypertension34; however, it is 
unknown whether this association occurs in patients with milder CKD. The only available 
pediatric study showed that children with mild to moderate ARPKD had neurocognitive 
functioning comparable with children with other causes of CKD across IQ, academic 
achievement, attention/executive functioning, and behavior39. To date, there is limited 
literature to explicitly guide clinical practice around neurodevelopmental and 
socialbehavioral issues in ARPKD children.
Expert opinion
• An interdisciplinary team model is suggested, that ideally would include a 
consulting psychologist or neuropsychologist with specialized knowledge of CKD 
and the associated co-morbid conditions.
• The team should engage in systematic developmental surveillance, (e.g. brief 
annual or biannual screenings), to track cognitive, social, and behavioral 
functioning over time, as well as track parent and child quality of life and 
adherence to medical treatment.
• Neuropsychological assessment may be indicated for those children with signs of 
learning/attention problems and for those who manifest behavioral/emotional 
difficulties.
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